X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NOVARTIS ALEMBIC PHARMA/
NOVARTIS
 
P/E (TTM) x 19.6 261.0 7.5% View Chart
P/BV x 5.1 22.2 23.1% View Chart
Dividend Yield % 0.9 1.6 55.9%  

Financials

 ALEMBIC PHARMA   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
NOVARTIS
Mar-17
ALEMBIC PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs792855 92.6%   
Low Rs443666 66.6%   
Sales per share (Unadj.) Rs167.0219.0 76.3%  
Earnings per share (Unadj.) Rs38.219.1 199.8%  
Cash flow per share (Unadj.) Rs42.020.3 206.9%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.61.3 49.3%  
Book value per share (Unadj.) Rs84.9307.0 27.7%  
Shares outstanding (eoy) m188.5229.96 629.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.5 106.5%   
Avg P/E ratio x16.239.8 40.6%  
P/CF ratio (eoy) x14.737.5 39.2%  
Price / Book Value ratio x7.32.5 293.6%  
Dividend payout %10.552.4 20.0%   
Avg Mkt Cap Rs m116,38322,779 510.9%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m4,2141,393 302.5%   
Avg. sales/employee Rs ThNM9,736.2-  
Avg. wages/employee Rs ThNM2,066.8-  
Avg. net profit/employee Rs ThNM849.0-  
INCOME DATA
Net Sales Rs m31,4876,562 479.8%  
Other income Rs m55702 7.9%   
Total revenues Rs m31,5427,264 434.2%   
Gross profit Rs m10,060259 3,885.6%  
Depreciation Rs m72236 2,011.4%   
Interest Rs m377 511.1%   
Profit before tax Rs m9,356917 1,019.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160345 626.0%   
Profit after tax Rs m7,194572 1,257.3%  
Gross profit margin %31.93.9 809.8%  
Effective tax rate %23.137.6 61.4%   
Net profit margin %22.88.7 262.0%  
BALANCE SHEET DATA
Current assets Rs m15,0669,731 154.8%   
Current liabilities Rs m7,6741,830 419.3%   
Net working cap to sales %23.5120.4 19.5%  
Current ratio x2.05.3 36.9%  
Inventory Days Days6749 137.5%  
Debtors Days Days4125 161.5%  
Net fixed assets Rs m8,23757 14,401.1%   
Share capital Rs m377141 267.9%   
"Free" reserves Rs m15,4169,056 170.2%   
Net worth Rs m16,0059,196 174.0%   
Long term debt Rs m00-   
Total assets Rs m24,59411,499 213.9%  
Interest coverage x255.2128.4 198.8%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.6 224.4%   
Return on assets %29.45.0 583.5%  
Return on equity %44.96.2 722.4%  
Return on capital %58.710.1 583.7%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,811129 13,817.3%   
Fx outflow Rs m5,3181,734 306.7%   
Net fx Rs m12,493-1,605 -778.3%   
CASH FLOW
From Operations Rs m9,304-380 -2,451.6%  
From Investments Rs m-3,1054,208 -73.8%  
From Financial Activity Rs m-1,959-3,318 59.0%  
Net Cashflow Rs m4,240510 831.2%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 2.0 145.0%  
FIIs % 9.1 1.6 568.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.5 64.7%  
Shareholders   49,328 41,647 118.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   UNICHEM LAB  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day Flat; Auto Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a positive note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 22, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS